Literature DB >> 10822070

Antiphospholipid antibodies in children without and in adults with and without thrombophilia.

H J Siemens1, S Gutsche, S Brückner, P Bucsky, H A Katus.   

Abstract

Antiphospholipid antibodies (APAs) are considered risk factors in patients with thromboembolic diseases. Although the incidence of such acquired coagulation disturbances in adults are well described, only few data exist for children. Therefore, in a first step to collect new data we analyzed the presence of different APAs in 202 consecutive children and compared them with two groups of adults. The children screened for APA were exclusively those who did not have any thromboembolic complications or a tendency for thrombophilia due to other underlying diseases such as systemic lupus or malignancy in their past or present medical history. Consecutive blood samples were evaluated from routine laboratory specimens. The two groups of adults comprised 200 patients after deep vein thrombosis and 200 patients without thromboembolic events that served as controls. Four lupus anticoagulant (LA) screening tests were determined: the dilute Russell's viper venom test; a lupus anticoagulant-sensitive activated partial thromboplastin time reagent; a second lupus-sensitive activated partial thromboplastin time; and the Kaolin clotting time. Furthermore, three different antiphospholipid antibodies ELISA assays against cardiolipin (ACA), beta2-glycoprotein I, and phosphatidyl-serine, were determined. The children had a much higher prevalence for LA than did the adults. On the other hand, their values for ACA were significantly lower than in adults with a history of thromboembolism. Findings in children were similar to the normal adult group. This has to be taken into account when evaluating children with thromboembolic diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822070     DOI: 10.1016/s0049-3848(99)00241-8

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  Clinical relevance of anti-phospholipid antibody tests in childhood.

Authors:  Tamás Constantin; Andrea Ponyi; György Fekete
Journal:  Eur J Pediatr       Date:  2004-05-27       Impact factor: 3.183

2.  Antiphospholipid syndrome accompanied by a silent splenic infarct in a patient with juvenile SLE.

Authors:  Tamás Constantin; Andrea Ponyi; Edit Varga; Katalin Dankó; György Fekete; Gábor Kovács
Journal:  Rheumatol Int       Date:  2006-04-20       Impact factor: 2.631

Review 3.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

4.  Clinical and laboratory characteristics of children positive for antiphospholipid antibodies.

Authors:  Paola Giordano; Riccardina Tesse; Giuseppe Lassandro; Deborah Fracchiolla; Prudenza Ranieri; Antonella Lotito; Domenico De Mattia; Giovanni Carlo Del Vecchio
Journal:  Blood Transfus       Date:  2011-12-21       Impact factor: 3.443

Review 5.  Pediatric antiphospholipid syndrome.

Authors:  Jacqueline A Madison; Yu Zuo; Jason S Knight
Journal:  Eur J Rheumatol       Date:  2019-12-03

6.  Infant stroke and beta-2-glycoprotein 1 antibodies: six cases.

Authors:  Freja Ebeling; Jari Petäjä; Soile Alanko; Aune Hirvasniemi; Tarja Holm; Marja Lähde; Auli Nuutila; Helena Pesonen; Elina Vahtera; Vesa Rasi
Journal:  Eur J Pediatr       Date:  2003-08-12       Impact factor: 3.183

Review 7.  Antiphospholipid antibodies in pediatrics.

Authors:  Ana I Quintero-Del-Rio
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

Review 8.  Autoimmunity in Acute Poststreptococcal GN: A Neglected Aspect of the Disease.

Authors:  Bernardo Rodriguez-Iturbe
Journal:  J Am Soc Nephrol       Date:  2021-02-02       Impact factor: 10.121

Review 9.  Epidemiology of Antiphospholipid Syndrome in the General Population.

Authors:  Jesse Y Dabit; Maria O Valenzuela-Almada; Sebastian Vallejo-Ramos; Alí Duarte-García
Journal:  Curr Rheumatol Rep       Date:  2022-01-05       Impact factor: 4.592

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.